Key facts
- This page summarizes Charles J. Casamento's Form 4 filing for First Wave BioPharma, Inc. (ENTO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Jan 2024, 17:14.
Charles J. Casamento - 02 Jan 2024 Form 4 Insider Report for First Wave BioPharma, Inc. (ENTO)
- Reporting relationship
- Director
- Issuer ticker
- ENTO
- Reported as of
- 02 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2024, 17:14:27 UTC
- Prior SEC filing
- 19 Dec 2023
- Next SEC filing
- 31 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles J. Casamento
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles J. Casamento filed Form 4 for First Wave BioPharma, Inc. (ENTO) on 04 Jan 2024.
Change
- Previous filing in this sequence was filed on 19 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FWBI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +19,633
- Change %
- +6458%
- Price
- $0.000000
- Shares after
- 19,937
- Date
- 02 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
Footnote F2
Includes unvested RSUs.